Comparative Pharmacology
Head-to-head clinical analysis: ETHOSUXIMIDE versus VALRELEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHOSUXIMIDE versus VALRELEASE.
ETHOSUXIMIDE vs VALRELEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethosuximide reduces the frequency of spike-and-wave discharges in absence seizures by blocking T-type calcium channels in thalamic neurons, thereby stabilizing neuronal membrane and preventing rhythmic burst firing.
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Adults: 500 mg orally twice daily initially, increase by 250 mg every 4-7 days as needed; maintenance dose 1-2 g/day divided into 2-4 doses. Maximum 1.5 g/dose or 3 g/day.
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 60 hours (range 40–60 hours) in adults; children may have shorter half-life (~30–40 hours). Long half-life allows once- or twice-daily dosing.
Clinical Note
moderateEthosuximide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Fluconazole
Terminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels.
Primarily renal excretion; ~20% as unchanged ethosuximide and ~50% as conjugated metabolite (glucuronide plus minor hydroxymetabolites). Less than 5% eliminated via feces.
Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Ethosuximide."